Menu
 
Tuesday | Wednesday | Thursday | Friday | Saturday
THURSDAY, DECEMBER 10, 2015
     
7:00 am - 5:15 pm Registration - Bridge Hall  
     
 7:30 am - 9:00 am Poster Discussion 3 - Novel Targets - Ballroom A  
  Trey Westbrook, PhD, Co-Discussant
Baylor College of Medicine
Houston, TX
and
Steven D. Weitman, MD, PhD, Co-Discussant
UT Health Science Center
San Antonio, TX
 
     
7:30 am - 9:00 am

POSTER SESSION 2 & continental breakfast - Halls A-B

 
     
 

Detection/Diagnosis

 
 

Circulating Markers

Circulating Tumor Cells

P2-01

P2-02

 

Tumor Cell and Molecular Biology

 
 

Micro RNAs

Epigenetics

Tumor Progression, Invasion, and Metastasis

Oncogenes/Tumor Suppressor Genes

P2-03

P2-04

P2-05

P2-06

  Prognostic and Predictive Factors  
 

Prognostic Factors - Preclinical

Prognostic Factors - Clinical Testing and Validation

P2-07

P2-08

  Epidemiology, Risk, and Prevention  
 

Famililal Breast Cancer - Genetic Testing

Familial Breast Cancer - Molecular Genetics

P2-09

P2-10

  Treatment  
  Immunotherapy (Clinical)
Surgery
Reconstruction
P2-11
P2-12
P2-13
     
9:00 am - 9:30 am PLENARY LECTURE 2 – Hall D  
 

Clonal Dynamics and Breast Cancer Subtypes

Samuel Aparicio, BM, BCh, PhD, FRCPath
The University of British Columbia
Vancouver, CANADA

 
     
9:30 am - 11:30 am

GENERAL SESSION 3 – Hall D

 
     
9:30 am

S3-01. EndoPredict (EPclin) score for estimating residual distant recurrence (DR) risk in ER+/HER2- breast cancer (br ca) patients treated with 5 years adjuvant endocrine therapy alone: Validation and comparison with the oncotype DX recurrence score (RS) 

Dowsett M, Sestak I, Buus R, Kronenwett R, Denkert C, Krappmann K, Scheer M, Petry C, Dubsky P, Cuzick J.  Institute of Cancer Research, London, United Kingdom; Royal Marsden Hospital, London, United Kingdom; Queen Mary University of London, London, United Kingdom; Sividon Diagnostics, Cologne, Germany; Charité Universitätsmedizin Berlin, Berlin, Germany; Medical University Vienna, Vienna, Austria

 
     
9:45 am

S3-02. Molecular predictors of outcome on adjuvant CAF plus tamoxifen (T) vs T in postmenopausal patients (pts) with ER+, node+ breast cancer – Transcriptome expression analysis of the phase III trial SWOG-8814
Albain KS, Crager MR, Barlow WE, Baehner FL, Bergamaschi A, Rae JM, Ravdin PM, Tripathy D, Gralow JR, Livingston RB, Osborne CK, Ingle JN, Pritchard KI, Davidson NE, Carey LA, Cherbavaz DB, Sing AP, Shak S, Hortobagyi GN, Hayes DF.  Loyola Univ Chicago Stritch School of Medicine, Maywood, IL; Genomic Health, Inc., Redwood City, CA; Cancer Research and Biostatistics, Seattle, WA; Genomic Health, Inc. and Univ of California, San Francisco, Redwood City and San Francisco, CA; University of Michigan, Ann Arbor, MI; University of Texas Health Science Center Cancer Therapy and Research Center, San Antonio, TX; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Washington, Seattle Cancer Care Alliance, Seattle, WA; University of Arizona Cancer Center, Tucson, AZ; Baylor College of Medicine, Houston, TX; Mayo Clinic, Rochester, MN; Sunnybrook Odette Cancer Centre and the University of Toronto, Toronto, Ontario, Canada; University of Pittsburgh Medical Center, Pittsburgh, PA; University of North Carolina at Chapel Hill, Chapel Hill, NC.

 
     
10:00 am

S3-03. Nuclear FGFR1 interaction with estrogen receptor (ER) α is associated with resistance to endocrine therapy in ER+/FGFR1-amplified breast cancer
Formisano L, Young CD, Bhola NE, Bulen B, Estrada VM, Wagle N, Van Allen E, Red Brewer ML, Jansen VM, Guerrero AL, Giltnane JM, Strcker T, Arteaga CL.  Vanderbilt University Medical Center; University of Naples 'Federico II' and Broad Institute of Harvard & MIT.

 
     
10:15 am

S3-04. ESR1 coregulator binding inhibitor (ECBI) as a novel therapeutic to target hormone therapy resistant metastatic breast cancer
Vadlamudi RK, Sareddy GR, Viswanadhapalli S, Lee T-K, Ma S-H, Lee WR, Mann M, Krishnan SR, Gonugunta V, Strand DW, Tekmal RR, Ahn J-M, Raj GV. UT Health Science Center San Antonio, San Antonio, TX; UT Southwestern Medical Center, Dallas, TX; UT Dallas, Dallas, TX.

 
     
10:30 am

S3-05.  Higher 10-year overall survival after breast conserving therapy compared to mastectomy in early stage breast cancer: a population-based study with 37,207 patients 
van Maaren MC, de Munck L, de Bock GH, Jobsen JJ, van Dalen T, Poortmans P, Linn S, Strobbe LJA, Siesling S.  Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands; University of Groningen, University Medical Center Groningen, Groningen, Netherlands; Medical Spectrum Twente, Enschede, Netherlands; Diakonessenhuis Utrecht, Utrecht, Netherlands; Radboud University Medical Center, Nijmegen, Netherlands; Netherlands Cancer Institute, Amsterdam, Netherlands; Canisius Wilhelmina Hospital, Nijmegen, Netherlands; MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, Netherlands.

 
     
10:45 am

S3-06.  Treatment outcomes in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast MR imaging: Results of a secondary analysis of TBCRC 017
De Los Santos J, Hyslop T, Alvarado M, Forero A, Golshan M, Hieken T, Horton J, Hudis C, McGuire K, Meric-Bernstam F, Nanda R, Zagar T, Hwang S.  University of Alabama at Birmingham, Birmingham, AL; Duke Cancer Institute, Durham, NC; University of California San Francisco, San Francisco, CA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University School of Medicine, Durham, NC; Memorial Sloan Kettering Cancer Center, New York, NY; University of Pittsburgh Medical Center, Pittsburgh, PA; The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Chicago Medicine, Chicago, IL; University of North Carolina at Chapel Hill, Chapel Hill, NC.

 
     
11:00 am

S3-07.  Complication and economic burden of local therapy options for early breast cancer
Smith BD, Jiang J, Shih Y-CT, Giordano SH, Huo J, Jagsi R, Caudle AS, Hunt KK, Shaitelman SF, Buchholz TA, Shirvani SM.   The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Michigan, Ann Arbor, MI; Banner MD Anderson Cancer Center, Gilbert, AZ.

 
     
11:15 am

S3-08.  Discussant

Ismail Jatoi, MD, PhD, FACS
UT Health Science Center
San Antonio, TX

 
      

11:30 am

AACR  Distinguished Lectureship in Breast Cancer Research - Hall D

 
  Molecular Evolution Under Neoadjuvant Chemotherapy
Anne-Lise Børresen-Dale, DSc
Oslo University Hospital
Oslo, NORWAY
 
      

12:00 pm - 1:00 pm LUNCH AND EXHIBITS  
     
1:00 pm - 2:00 pm

CASE DISCUSSION 1 – Ballroom A

 
  Moderator: Mothaffar Rimawi, MD, Baylor College of Medicine, Houston, TX  
  Panelists:

Jennifer De Los Santos, MD
University of Alabama-Birmingham
Birmingham, AL

Judy Johnson
Komen Advocates in Science
St. Louis, MO

Suleiman Massarweh, MD
Stanford University
Stanford, CA

Ingrid Meszoely, MD
Vanderbilt University
Nashville, TN

Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA
 
      

1:00 pm - 2:00 pm BASIC SCIENCE FORUM - Ballroom B  
 

Novel and Unconventional Drivers of Breast Tumorigenesis

Moderator: Yi Li, PhD, Baylor College of Medicine, Houston, TX

Insights from a compendium of 560 whole-genome sequenced breast cancers

Serena Nik-Zainal, PhD, MRCP, MB BChir

The Wellcome Trust Sanger Institute

Hinxton, UNITED KINGDOM

Roles of epigenetic regulation in breast cancer development

Michael R. Green, MD, PhD

Howard Hughes Medical Institute

Chevy Chase, MD

 
      

2:15 pm - 3:15 pm MINI-SYMPOSIUM 1 - Hall D  
 

Cell Cycle Regulation: CDK Inhibitors

Moderator: George W. Sledge, Jr., MD, Stanford University, Stanford, CA

 
 

Beyond CDK 4/6: Targeting additional cell cycle and transcriptional CDKs in breast cancer

Geoffrey Shapiro, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

Targeting CDK 4/6 in breast cancer

Richard Finn, MD
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, CA

 
     
3:15 pm - 5:00 pm

GENERAL SESSION 4 – Hall D

 
     
3:15 pm

S4-01. Identification of early versus late drivers of breast tumors and metastasis

Siegel MB, He X, Chen M, Hou JP, Garrett AL, Dye JB, Silva GO, Usary JE, Moylan VJ, Brady CM, Ma J, Thorne LB, Hoadley KA, Parker JS, Anders CK, Carey LA, Perou CM. University of North Carolina at Chapel Hill, Chapel Hill, NC; University of Illinois at Urbana-Champaign, Urbana, IL.
 
     
3:30 pm

S4-02. A comprehensive analysis of fusion transcripts in breast cancer reveals associations between number of fusion transcripts, copy number events, gene expression profiles, and potentially clinical outcome

Thompson EA, Asmann YW, Su X, Ellis MJ, Shao J, Hu Y, White KP, Cherniack AD, Hoadley KA, Serie DJ, Perez EA, Perou CM. Mayo Clinic Comprehensive Cancer Center, Jacksonville, FL; MD Anderson Comprehensive Cancer Center, Houston, TX; Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; Sage Bionetworks, Seattle, WA; University of Chicago, Chicago, IL; Broad Institute, Cambridge, MA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC.

 
     
3:45 pm

S4-03. A functional assay for homologous recombination (HR) DNA repair and whole exome sequencing reveal that HR-defective sporadic breast cancers are enriched for genetic alterations in DNA repair genes 
Powell SN, Riaz N, Mutter RW, Ng CKY, Delsite R, Piscuoglio S, King TA, Martelotto L, Sakr R, Brogi E, Edelweiss M, Lim R, Higginson D, Weigelt B, Lee W, Reis-Filho JS. Memorial Sloan Kettering Cancer Center, New York, NY; Mayo Clinic, Rochester, MN.

 
     
4:00 pm

S4-04. Lobular carcinoma in situ displays intra-lesion genetic heterogeneity and its progression to invasive disease involves clonal selection and variations in mutational processes 
Reis-Filho JS, Schizas M, Piscuoglio S, Sakr RA, Ng CKY, Lim RS, Carniello JVS, Towers R, Martelotto L, Giri DD, de Andrade VP, Viale A, Solit DB, Weigelt B, King TA. Memorial Sloan Kettering Cancer Center, New York, NY; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.

 
     
4:15 pm

S4-05. Interrogating the landscape of long noncoding RNAs in breast cancer to identify predictors of tamoxifen resistance

Feng FY, Niknafs Y, Han S, Ma T, Speers C, Malik R, Evans J, Zhang C, Pierce LJ, Hayes DF, Rae JM, Chinnaiyan AM.  University of Michigan, Ann Arbor, MI.

 
     
 4:30 pm S4-06. HER2 status as predictive marker for AI vs Tam benefit: a TRANS-AIOG meta-analysis of 12129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2

Bartlett JMS, Ahmed I, Regan MM, Sestak I, Mallon EA, Dell'Orto P, Thürlimann BJK, Seynaeve C, Putter H, Brookes CL, Forbes JF, Colleoni MA, Bayani J, van de Velde CJH, Viale G, Cuzick J, Dowsett M, Rea DW, On Behalf of the Translational Aromatase Inhibitor Overview Group (Trans-AIOG).  Ontario Institute for Cancer Research, Toronto, ON, Canada; University of Birmingham, Birmingham, United Kingdom; Dana-Farber Cancer Institute, Boston, MA; Queen Mary, University of London, London, United Kingdom; Western Infirmary, Glasgow, United Kingdom; Breast Center, Kantonsspital St. Gallen, St. Gallen, Switzerland; Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands; The University of Newcastle, Newcastle, New South Wales, Australia; University of Milan, Milan, Italy; Royal Marsden Hospital, London, United Kingdom; European Institute of Oncology, Milan, Italy.

 
     
 4:45 pm S4-07. Tamoxifen resistance driven by the DNA cytosine deaminase APOBEC3B in recurrent estrogen receptor positive breast cancer

Harris R, Law E, Sieuwerts A, LaPara K, Leonard B, Starrett G, Temiz NA, Sweep F, Span P, Foekens J, Martens J, Yee D. University of Minnesota, Minneapolis, MN; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Radboud University Medical Center, Nijmegen, Netherlands. 
 


5:00 pm - 7:00 pm

POSTER DISCUSSION 4: Barriers to Care and Quality of Life – Ballroom B

 
  Norah Lynn Henry, MD, PhD, Co-Discussant
University of Michigan Comprehensive Cancer Center
Ann Arbor, MI
and
Vanessa B. Sheppard, PhD, Co-Discussant
Georgetown University
Washington, DC
 
     
5:00 pm - 7:00 pm

POSTER DISCUSSION 5: HER2 – Ballroom A

 
  Ron Bose, MD, PhD, Co-Discussant
Washington University in St. Louis
St. Louis, MO
and
Ian E. Krop, MD, PhD, Co-Discussant
Dana-Farber Cancer Institute
Boston, MA
 
     
5:00 pm - 7:00 pm POSTER SESSION 3 & reception – Halls A-B
     

Detection/Diagnosis

Axillary Staging and Sentinel Nodes

P3-01

     
 

Tumor Cell and Molecular Biology

Angiogenesis

Animal Models

Hormonal Factors and Receptors

Endocrine Therapy and Resistance

Drug Resistance

P3-02

P3-03

P3-04

P3-05

P3-06

 
 
 

Prognostic and Predictive Factors

Response Predictions - Biomarkers and Other Factors

P3-07

     
 

Epidemiology, Risk, and Prevention

Prevention - Behavioral Interventions

Prevention - Nutritional Studies

Prevention - Clinical Trials

Prevention - Preclinical Studies and Model Systems

P3-08

P3-09

P3-10

P3-11

     
 

Treatment

Radiotherapy

Breast Conservation

Novel Targets and Targeted Agents

P3-12

P3-13

P3-14



 

Ongoing Clinical Trials 2

Endocrine Therapies

Surgery and Radiation

Prognostic and Predictive Factors

Patient Management

Tumor Biology, Genetics, Genomics

OT2-1

OT2-2

OT2-3

OT2-4

OT2-5

     
 
Tuesday | Wednesday | Thursday | Friday | Saturday